People
Oxford University, which by many standards is ahead of everyone in the vaccine development world, is suggesting end of the year is possible, but being very cautious about it.
The trial was initially scheduled for July, but in April had been postponed until October due to the pandemic. A final decision will be made in August.
The trendy drug brand names for 2020 include Tepezza®, Zolgensma®, and Qvar®. Like the names of newborn children, they are designed to be visually distinctive and to make a statement.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.
Today BioSpace released its second annual 2020 U.S. Life Sciences Salary Report, revealing surprising – and sometimes shocking – results. Here’s a look at some of the topline data.
Metagenomics can look across the entire genomic sequence of more than 50,000 species of organisms that may be present in a patient sample and compare millions of sequences from a patient with millions of reference sequences.
Ken Frazier, Merck’s chief executive officer, is reminding the world that vaccine development takes time, typically a decade, and hoping for a viable vaccine against the novel coronavirus by the end of December is premature.
What do you get when you mix certain immune cells with vitamin D and a disease-provoking molecule? An innovative new vaccine for type 1 diabetes.
Thomas Olin, chief executive officer of Kancera, took time to discuss the company, the Fracktalkine pathway and the upcoming clinical trial.
PRESS RELEASES